NEW YORK (GenomeWeb) – The US Food and Drug Administration has granted 510(k) clearance to a Clostridium difficile test from Roche, the firm announced today.

The test detects the C. diff toxin B gene from stool samples. It runs on Roche's cobas 4800 system, which combines automated sample preparation with real-time PCR amplification and detection for mixed batch testing.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.